The anti-IgE therapy omalizumab, which impedes IgE-dependent cellular events by binding to free IgE, prevents binding of IgE to FcɛRI, and reduces the expression of FcɛRI, was the first biologic therapy to be licensed as an add-on treatment for patients with moderate-to-severe asthma [14]. Here, IGHE is linked to asthma.